Reminder to self/CEGE Mon March 25 11:20 a.m. EST
(thank you Wilder)
Maybe we will hear something more about
what Rigel has done for cege in the way
of angiogenesis targets.
Press Release
SOURCE: Cell Genesys
Cell Genesys Invites You to Join Its Company Presentation at the New York Society of Security Analysts 6th Annual Health Care Conference on the Web
NEW YORK, March 22 /PRNewswire/ -- In conjunction with Cell Genesys' company presentation at the New York Society of Security Analysts (NYSSA) 6th Annual Health Care Conference, you are invited to listen to the presentation that will be broadcast live over the Internet on Monday, March 25, 2002, at 11:20 a.m. EST with Matthew J. Pfeffer, vice president and chief financial officer of Cell Genesys (Nasdaq: CEGE - news). Mr. Pfeffer is expected to provide an update on plans for presentations describing certain of the company's clinical programs at the May 2002 meeting of the American Society of Clinical Oncology (ASCO).
What: Cell Genesys Company Update
NYSSA 6th Annual Health Care Conference
When: Monday, March 25, 2002, at 11:20 a.m. EST
Where: www.cellgenesys.com
How: Live over the Internet -- Simply log on to the web at the
address above
Contact: Jennifer Cook Williams
650-425-4542
Cell Genesys is focused on the development and commercialization of innovative therapeutic products for cancer based on gene therapy technologies. The company is pursuing three cancer product platforms -- GVAX® cancer vaccines, oncolytic virus therapies and in vivo cancer gene therapies. Clinical trials of GVAX® vaccines are under way in lung cancer, prostate cancer, pancreatic cancer, leukemia and myeloma. Clinical trials of oncolytic virus therapies include CG7060 and CG7870 in prostate cancer. Preclinical stage programs include oncolytic virus therapies and gene therapies for multiple types of cancer. Cell Genesys' majority-owned subsidiary, Ceregene, is focused on gene therapies for neurologic disorders. Cell Genesys also continues to hold approximately nine million shares of common stock in its former subsidiary, Abgenix, an antibody products company. Cell Genesys is headquartered in Foster City, CA and has manufacturing operations in San Diego, CA, Hayward, CA and Memphis, TN. For additional information, please visit the company's website at www.cellgenesys.com.
If you are unable to listen to the live webcast, the presentation will be archived on www.cellgenesys.com and will be available within one hour following the presentation for two weeks.
SOURCE: Cell Genesys |
